A61K36/068

Method for preventing, postponing or treating changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment

The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35 C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35 C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35 C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

Method for preventing, postponing or treating changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment

The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35 C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35 C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35 C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

COMPOSITION OF DIETARY SUPPLEMENTS AND METHODS OF MAKING THEREOF
20200281242 · 2020-09-10 ·

Disclosed are dietary supplement compositions and methods of making the dietary supplements in capsule form. For example, dietary supplement composition having Oryza sativa Linn, Cordyceps militaris, Ardisia polycephala Wall, Smilax corbularia Kunth, Smilax glabra Rhizome, cereal enzymes, Fomes rimosus (Berk.) Cooke, and edible bird's nest are provided.

COMPOSITION OF DIETARY SUPPLEMENTS AND METHODS OF MAKING THEREOF
20200281242 · 2020-09-10 ·

Disclosed are dietary supplement compositions and methods of making the dietary supplements in capsule form. For example, dietary supplement composition having Oryza sativa Linn, Cordyceps militaris, Ardisia polycephala Wall, Smilax corbularia Kunth, Smilax glabra Rhizome, cereal enzymes, Fomes rimosus (Berk.) Cooke, and edible bird's nest are provided.

BIOPHOTONIC COMPOSITIONS COMPRISING A FUNGAL-DERIVED CHROMOPHORE

The present disclosure provides biophotonic compositions comprising one or more fungal-derived chromophores and methods useful in phototherapy. In particular, the biophotonic compositions and the methods of the present disclosure are useful for the treatment of rare diseases that afflict skin or soft tissues. The present disclosure also provides a photoactivatable fabric composition in combination with the biophotonic compositions.

BIOPHOTONIC COMPOSITIONS COMPRISING A FUNGAL-DERIVED CHROMOPHORE

The present disclosure provides biophotonic compositions comprising one or more fungal-derived chromophores and methods useful in phototherapy. In particular, the biophotonic compositions and the methods of the present disclosure are useful for the treatment of rare diseases that afflict skin or soft tissues. The present disclosure also provides a photoactivatable fabric composition in combination with the biophotonic compositions.

Fresh Ophiocordyceps sinensis product and preparation method thereof

The present disclosure pertains to the field of processing fresh traditional Chinese medicinal materials, and particularly relates to a method of preparing a fresh Ophiocordyceps sinensis product. The fresh Ophiocordyceps sinensis product may be prepared by the following steps: 1) stripping off mud from a fresh Ophiocordyceps sinensis; 2) brushing with flowing water; 3) cleaning ultrasonically; 4) humidifying the cleaned fresh Ophiocordyceps sinensis with atomized water for 15 to 20 minutes; 5) packaging the humidified fresh Ophiocordyceps sinensis by sealing it in a tube charged with a modified-atmosphere; and 6) storing the tube at a low temperature; wherein step 1) to step 4) are carried out at a temperature from 3 to 15 C. The present disclosure also relates to a fresh Ophiocordyceps sinensis product prepared by the above method.

Fresh Ophiocordyceps sinensis product and preparation method thereof

The present disclosure pertains to the field of processing fresh traditional Chinese medicinal materials, and particularly relates to a method of preparing a fresh Ophiocordyceps sinensis product. The fresh Ophiocordyceps sinensis product may be prepared by the following steps: 1) stripping off mud from a fresh Ophiocordyceps sinensis; 2) brushing with flowing water; 3) cleaning ultrasonically; 4) humidifying the cleaned fresh Ophiocordyceps sinensis with atomized water for 15 to 20 minutes; 5) packaging the humidified fresh Ophiocordyceps sinensis by sealing it in a tube charged with a modified-atmosphere; and 6) storing the tube at a low temperature; wherein step 1) to step 4) are carried out at a temperature from 3 to 15 C. The present disclosure also relates to a fresh Ophiocordyceps sinensis product prepared by the above method.

Orally consumable cannabinoid composition including lecithin
10617733 · 2020-04-14 · ·

The present invention relates to a pharmaceutical composition comprising non-decarboxylated 9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.

Orally consumable cannabinoid composition including lecithin
10617733 · 2020-04-14 · ·

The present invention relates to a pharmaceutical composition comprising non-decarboxylated 9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.